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Abstract
Background: Perifosine, an alkylphospholipid tested in phase II clinical trials, modulates the extrinsic apoptotic
pathway and cooperates with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to augment
apoptosis. The current study focuses on revealing the mechanisms by which perifosine enhances TRAIL-induced
apoptosis.
Results: The combination of perifosine and TRAIL was more active than each single agent alone in inducing
apoptosis of head and neck squamous cell carcinoma cells and inhibiting the growth of xenografts. Interestingly,
perifosine primarily increased cell surface levels of DR5 although it elevated the expression of both DR4 and DR5.
Blockade of DR5, but not DR4 upregulation, via small interfering RNA (siRNA) inhibited perifosine/TRAIL-induced
apoptosis. Perifosine increased phosphorylated c-Jun NH2-terminal kinase (JNK) and c-Jun levels, which were
paralleled with DR4 and DR5 induction. However, only DR5 upregulaiton induced by perifosine could be abrogated
by both the JNK inhibitor SP600125 and JNK siRNA. The antioxidants, N-acetylcysteine and glutathione, but not
vitamin C or tiron, inhibited perifosine-induced elevation of p-c-Jun, DR4 and DR5. Moreover, no increased
production of reactive oxygen species was detected in perifosine-treated cells although reduced levels of
intracellular GSH were measured.
Conclusions: DR5 induction plays a critical role in mediating perifosine/TRAIL-induced apoptosis. Perifosine induces
DR5 expression through a JNK-dependent mechanism independent of reactive oxygen species.
Background
Perifosine, the first orally bioavailable alkylphospholipid,
has shown antitumor activity in preclinical models and
is currently in Phase II clinical trials [1,2]. The mechan-
isms underlying perifosine-mediated antitumor effects
have not been fully elucidated, although it is known to
i n h i b i tA k t[ 3 , 4 ]a n di n d u c ec - J u nN H 2-terminal kinase
(JNK) activation [5-7]. Perifosine has also been shown to
induce p21 expression, leading to cell cycle arrest [8]. In
addition, perifosine in combination with other antitumor
agents such as the PDK1 inhibitor, UCN-01 [9], histone
deacetylase inhibitors [10], and the chemotherapeutic
agent etoposide [11] show synergistic antitumor effects.
Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL; also called APO-2L), a member
of the TNF family, induces apoptosis preferentially in
transformed or malignant cells, thus making it distinct
from the death ligands TNFa and Fas, which, in addi-
tion to inducing apoptosis in cancer cells, cause an
inflammatory response and liver damage, respectively,
when administered systemically [12,13]. Therefore,
TRAIL is currently being tested in phase I oncology
trials as a tumor-selective apoptosis-inducing cytokine.
Perifosine was previously reported to be active in
inhibiting the growth of head and neck squamous cell
carcinoma (HNSCC) cells [8]. However, a phase II trial
of perifosine in recurrent or metastatic head and neck
cancer failed to demonstrate the single-agent activity of
perifosine in HNSCC [14]. Therefore, we are interested
in developing perifosine-based combinations that exert
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have shown that perifosine increases DR5 expression
and cooperates with TRAIL to augment apoptosis in
human lung cancer and myeloma cells [15,16]. The cur-
rent study validated the cooperative induction of apop-
tosis by perifosine and TRAIL in human HNSCC cells
and examined their combinatorial effect on the growth
of HNSCC xenografts. Importantly, we were particularly
interested in revealing the possible mechanisms underly-
ing death receptor induction by perifosine and the coop-
erative induction of apoptosis by the perifosine/TRAIL
combination.
Methods
Reagents
Perifosine was supplied by Keryx Biopharmaceuticals,
Inc (New York, NY). This agent was dissolved in PBS
and stored at -20°C. Stock solution was diluted to the
appropriate concentrations with growth medium imme-
diately before use. Human recombinant TRAIL used in
cell cultures and in animals was purchased from Pepro-
Tech, Inc. (Rocky Hill, NJ) and prepared as previously
described [17]. The specific JNK inhibitor SP600125 was
purchased from Biomol (Plymouth Meeting, PA).
2’7’-dichlorofluorescein diacetate (DCF-DA) was pur-
chased from Molecular Probes (Eugene, OR). Mouse
anti-caspase-3 monoclonal antibody was purchased from
Imgenex (San Diego, CA). Rabbit polyclonal antibodies
against p-c-Jun (Ser63), c-Jun, p-ERK1/2 (Thr202/
Tyr204), ERK1/2, p-p38 (Thr180/Tyr182), p38, caspase-
8, caspase-9, and poly(ADP-ribose) polymerase (PARP)
were purchased from Cell Signaling Technology
(Beverly, MA). Rabbit polyclonal anti-DR5 antibody was
purchased from ProSci Inc (Poway, CA). Mouse mono-
clonal anti-DR4 antibody (B-N28) was purchased from
Diaclone (Stamford, CT). Rabbit anti-b-actin polyclonal
antibody and other chemicals were purchased from
Sigma Chemicals (St. Louis, MO).
Cell Lines and Cell Culture
The cell lines used in this study (M4e, 22A and 1483)
were described previously [18,19] and cultured in
Dulbecco’sm o d i f i e dE a g l e ’s medium (DMEM)/F12 sup-
plemented with 5% fetal bovine serum.
Cell Viability Assay
Cells were cultured in 96-well cell culture plates and
treated the next day with the agents indicated. Viable
cell numbers were estimated using the sulforhodamine
B (SRB) assay, as previously described [20].
Colony Formation Assay
Colony formation on plate was conducted in 12-well cell
culture plates as previously described [21].
Western Blot Analysis
Preparation of whole cell protein lysates and Western
blot analysis were described previously [22,23].
Detection of Caspase Activation and Apoptosis
Caspase activation and their substrate cleavage were
detected by Western blot analysis as described above.
Apoptosis was detected by estimating sub-G1 popula-
tion [24] or by measuring Annexin V positive cell num-
bers with Annexin V-phycoerythrin (PE) apoptosis
detection kit purchased from BD Biosciences (San Jose,
CA), following the manufacturer’s instructions.
Detection of Intracellular Reactive Oxygen Species (ROS)
and Glutathione (GSH)
Intracellular ROS generation was detected using the
oxidation-sensitive fluorescent dye DCF-DA as pre-
viously described [25]. The total intracellular GSH levels
were measured using monochlorobimane as a probe, as
previously described [26].
Detection of DR4 and DR5 mRNA Levels
Total cellular RNA isolation, cDNA synthesis and DR5
amplification were the same as described previously
[27]. DR4 and GAPDH were amplified by PCR using the
following primers: DR4 sense, 5’-CAGAGGGATGGT-
CAAGGTCAAGG-3’; DR4 antisense, 5’-CCACAACCT-
GAGCCGATGC-3’;G A P D Hs e n s e ,5 ’-TGATGACAT
CAAGAAGGTGGTGAAG-3’; and GAPDH antisense,
5’-TCCTTGGAGGCCATGTGGGCCAT-3’.F o rD R 4
amplification the 20 μL amplification mixture contained
1 μLo fc D N A ,0 . 6μLo fM g C l 2 (50 mM), 1 μL each of
the sense and antisense primers (20 μM each), 0.4 μLo f
dNTP (10 mM), 1 μL of iTaq DNA Polymerase (25
units/μL; Bio-Rad Laboratories), 2 μL 10 × reaction
buffer, and sterile H2O. PCR was done for 26 cycles.
After an initial step at 95°C for 3 minutes, each cycle
consisted of 30 sec of denaturation at 95°C, 30 sec of
annealing at 58°C, and 45 sec of extension at 72°C. This
was followed by an additional extension step at 72°C for
7 min. The housekeeping gene GAPDH was also ampli-
fied as an internal reference. PCR products were
resolved by electrophoresis on a 1.0% agarose gel,
stained, and directly visualized under UV illumination.
Detection of Cell Surface DR4 and DR5
The procedure for direct antibody staining and subse-
quent flow cytometric analysis of cell surface protein
was described previously [28,29]. The mean fluores-
cence intensity (MFI) that represents antigenic density
on a per cell basis was used to represent cell surface
DR5 or DR4 expression level. PE-conjugated mouse
anti-human DR5 (DJR2-4) and anti-human DR4 (DJR1)
monoclonal antibodies and PE mouse IgG1 isotype
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eBioscience (San Diego, CA).
Small Interfering RNA (siRNA)-mediated Gene Silencing
High purity control (non-silencing) and DR5 siRNA
oligos were described previously [22]. DR4 siRNA
targets the sequences 5’-AATGAGATCGATGTGGT-
CAGA-3’ (1239-1259). These siRNA oligos were synthe-
sized from Qiagen (Valencia, CA). JNK siRNAs (Cat No.
6234) were purchased from Cell Signaling Technology.
Transfection of these siRNA duplexes was conducted in
6-well plates using the HiPerFect transfection reagent
(Qiagen) following the manufacturer’sm a n u a l .F o r t y -
eight hours later, the cells were treated with or without
the combination of perifosine and TRAIL. Gene silen-
cing effect was evaluated by Western blot analysis.
HNSCC Orthotopic Xenograft Mouse Model
The animal experiment was approved by the Animal
Care and Use Committee of Emory University. Nude
mice (athymic nu/nu, Taconic, NY, USA) aged 4-6 weeks
were randomized into 4 groups. Each mouse was injected
with 1 × 10
6 M4e cells in 100 μl of PBS into the subman-
dibular to mylohyoid muscle as described previously [30].
A f t e ra b o u to n ew e e k ,t h em i c er e c e i v e dt h ef o l l o w i n g
treatments: vehicle control, perifosine (20 mg/kg; og),
TRAIL (20 mg/kg; ip) and perifosine plus TRAIL for
three weeks (once a day, 5 days of treatment plus two
days of break per week). The mice were then sacrificed
and the tumors were removed and weighed.
Results
Perifosine Cooperates with TRAIL to Augment Induction
of Apoptosis, Reduce Colony Formation and Inhibit the
Growth of HNSCC Xenografts
W ef i r s td e t e r m i n e dw h e t h e rperifosine combined with
TRAIL augmented the induction of apoptosis in
HNSCC cell lines. As presented in Figure 1A, the com-
bination of perifosine and TRAIL was more potent than
each single agent alone in decreasing the survival of
M4e and 22A cells. For example, perifosine at 2.5 μM
alone and TRAIL at 20 ng/ml alone decreased the survi-
val of M4e cells by less than 25%, whereas their combi-
nation decreased cell survival by greater than 75%. This
enhanced effect was minimal in 1483 cells. By measur-
ing apoptotic cells, we detected 56% apoptotic cells in
M4e cells exposed to the combination of perifosine and
TRAIL and <20% apoptotic cells in M4e cells treated
with either perifosine or TRAIL alone (Figure 1B). This
result further demonstrates that the combination
of perifosine and TRAIL exhibits a more than additive
(i.e., synergistic) effect on induction of apoptosis. Thus,
we conclude that perifosine cooperates with TRAIL to
synergistically trigger apoptosis of HNSCC cells.
Moreover, we analyzed the long-term effect of the
combination of perifosine and TRAIL on clonogenic
survival in cell culture and xenograft growth in nude
mice. In agreement with the apoptosis study, the combi-
nation of perifosine and TRAIL was much more potent
than either agent alone in suppressing colony formation.
Specifically the combination almost eliminated all colo-
nies, whereas perifosine or TRAIL alone only partially
inhibited the formation and growth of colonies (Figure
1C). Under the tested experimental conditions, we
found that the combination, but not perifosine alone or
TRAIL alone, also significantly inhibited the growth of
M4e xenografts (P < 0.05, Figure 1D). Thus, the combi-
nation of perifosine and TRAIL exhibits an enhanced
tumor-inhibitory effect in vivo.
Perifosine Upregulates the Expression of DR4 and DR5
To investigate how perifosine cooperates with TRAIL to
augment apoptosis, we examined the effects of perifo-
sine on the expression of DR4 and DR5, which are
k n o w nt ob eT R A I Ld e a t hr e c e p t o r s .A sp r e s e n t e di n
Figure 2A, both DR4 and DR5 were substantially
increased by perifosine in both M4e and 22A cell lines,
in which the perifosine and TRAIL combination exerted
augmented cell death-inducing effects, but not in 1483
cells, in which the combination did not exhibit an
enhanced cell death effect. In M4e cells, we further con-
ducted time-course analyses of the changes in expres-
sion of DR4 and DR5. As presented in Figure 2B,
upregulation of both DR4 and DR5 levels occurred at
3 h post perifosine treatment and was sustained for up
to 15 h. Collectively, these results indicate that the upre-
gulation of DR4 and DR5 by perifosine is an early event
that may contribute to cooperative induction of apopto-
sis by the perifosine and TRAIL combination.
Induction of DR5, but not DR4, Plays a Critical Role in
Mediating Cooperative Induction of Apoptosis by
Perifosine and TRAIL Combination
T od i s s e c tt h er o l e so fD R 4a n dD R 5m o d u l a t i o ni n
mediating perifosine/TRAIL-induced apoptosis, we used
a siRNA approach to block DR4 or DR5 induction
through silencing their expression and then examined
the impact on induction of apoptosis by the combina-
tion of perifosine and TRAIL. As shown in Figure 3,
transfection of DR4 or DR5 siRNA blocked perifosine-
induced upregulation of DR4 or DR5, indicating the
successful blockade of DR4 or DR5 induction,
respectively (Figures 3A and 3C). The combination of
perifosine and TRAIL increased the levels of cleaved
caspase-8, caspase-3 and PARP (Figure 3A) and apopto-
tic populations (Figure 3B) in control siRNA-transfected
cells. However, these effects of the combination were
clearly attenuated in cells transfected with DR5 siRNA
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induction exhibited no protective effects on the cleavage
of caspases and PARP and induction of apoptosis (Fig-
ures 3C and 3D) induced by the perifosine and TRAIL
combination when compared with control siRNA-trans-
fected cells. Thus, DR5 induction, but not DR4 upregu-
lation, plays an important role in mediating perifosine/
TRAIL-induced apoptosis.
Perifosine Increases Cell Surface Levels of DR5, but not
DR4
To further demonstrate the roles of DR4 and DR5 upregu-
lation in mediating perifosine/TRAIL-induced apoptosis,
we determined whether perifosine increases cell surface
levels of DR4 and/or DR5 with flow cytometry. As pre-
sented in Figure 4, the MFIs for DR5 in PBS control and
periforsine-treated cells were 32 and 46, respectively,
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Figure 1 The combination of perifosine and TRAIL exhibits enhanced effects on decreasing cell survival (A), inducing apoptosis (B)
and inhibiting colony formation (C) in HNSCC cell lines and augments xenograft growth inhibition (D). A, The indicated cell lines were
seeded in 96-well plates and the next day treated with the indicated concentrations of TRAIL alone, perifosine (PRFS) alone, or their respective
combinations (P + T). After 24 h, the cells were subjected to estimation of cell number using the SRB assay. The data are means ± SD of four
replicate determinations. B, M4e cells were treated with PBS control, 5 μM perifosine, 10 ng/ml TRAIL and the combination of perifosine and
TRAIL. After 24 h, apoptotic (sub-G1) cells were measured by flow cytometry. C, M4e cells plated in 12-well cell culture plates were treated with
1 μM perifosine, 10 ng/ml TRAIL, or their combination. The same treatments were repeated every 3 days. After 12 days, the plates were stained
for cell colonies with crystal violet dye, and photographs of colonies taken using a digital camera. D, Four groups of mice were treated with PBS
(n = 11), perifosine (n = 11), TRAIL (n = 13) and perifosine combined with TRAIL (n = 13), respectively, as described in “Materials and Methods”.
After about 3 weeks, the tumors were removed from the sacrificed mice and weighed. The data are means ± SD.
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DR5. However, perifosine did not increase cell surface
levels of DR4 because the MFIs for DR4 in PBS control
and periforsine-treated cells were 23 and 20, respectively.
Thus, it appears that perifosine specifically increases cell
surface levels of DR5 in the tested cell system.
Perifosine Induces DR4 and DR5 Expression at the
Transcriptional Level
Considering the critical role of DR5 induction in med-
iating the cooperative induction of apoptosis by perifo-
sine and TRAIL as documented above, we then focused
our further study on understanding how perifosine
induces DR5 expression in comparison with DR4 upre-
gulation. Thus, we asked whether perifosine regulates
the expression of DR5 and DR4 at the transcriptional
level. To this end, we first examined the effects of peri-
fosine on DR5 and DR4 expression in the presence of
the transcriptional inhibitor actinomycin D (Act D). As
shown in Figure 2C, perifosine increased the levels of
DR5 and DR4 in the absence, but not in the presence,
of Act D, indicating that inhibition of transcription
abolishes perifosine’s ability to increase DR5 and DR4
expression. Furthermore, we directly examined whether
perifosine increased the mRNA levels of DR5 and DR4.
As shown in Figure 2D, we detected dose-dependent
increases in DR5 and DR4 mRNAs in cells exposed to
perifosine. Collectively, we conclude that perifosine
increases the expression of DR5 and DR4 at the
transcriptional level.
Perifosine Induces JNK-dependent Expression of DR5
In addition to Akt inhibition, perifosine modulates other
signaling pathways such as ERK, p38 and JNK [7,31]. In
our cell system, perifosine rapidly increased the levels of
p-JNK and p-c-Jun while decreasing the levels of
p-ERK1/2 and p-p38 (Figure 5A), indicating that perifo-
sine activates JNK and suppresses ERK and p38 signal-
ing pathways. These results are consistent with a
previous report [7]. Given the drastic induction of DR5
and DR4 by perifosine as demonstrated above, we were
particularly interested in the mechanisms by which peri-
fosine induces expression of DR5 and DR4. In the same
cell system exposed to perifosine, we noted that both
DR4 and DR5 induction were kinetically paralleled with
p-c-Jun increase, both of which occurred after 3 h treat-
ment and reached a peak at 12 h treatment (Figures 2B
and 5A). Since JNK activation is linked to DR5
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Figure 2 Perifosine induces DR4 and DR5 expression (A and B) at the transcriptional level (C and D). A and B, The indicated cell lines
were treated with the given concentrations of perifosine (PRFS) for 16 h. C, M4e cells were pre-treated with the given concentrations of Act D
for 30 min and then co-treated with 10 μM perifosine for 8 h. After the aforementioned treatments, the cells were subjected to preparation of
whole-cell protein lysates and subsequent detection of the indicated proteins using Western blot analysis. D, M4e cells were treated with
indicated concentrations of perifosine for 7 h and then subjected to preparation of cellular total RNA and subsequent RT-PCR for detection of
DR4, DR5, and GAPDH (internal loading control).
Fu et al. Molecular Cancer 2010, 9:315
http://www.molecular-cancer.com/content/9/1/315
Page 5 of 13induction as we previously demonstrated [32], we then
asked whether perifosine induces DR5 and DR4 expres-
sion via a JNK-dependent mechanism. To this end, we
examined the effect of the JNK inhibitor SP600125
on perifosine-induced DR4 and DR5 expression.
The presence of SP600125 not only decreased basal
levels of p-c-Jun, DR4 and DR5, but also blocked perifo-
sine-induced increases in p-c-Jun, DR4 and DR5 expres-
sion (Figure 5B). To robustly demonstrate the role of
JNK activation in mediating perifosine-induced DR4 and
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Figure 3 siRNA-mediated inhibition of perifosine-induced upregulation of DR5 (A), but not DR4 (B), attenuates augmented induction
of apoptosis by the combination of perifosine and TRAIL. M4e cells were transfected with control (Ctrl), DR5 (A) or DR4 (B) siRNA. After 48
h, the cells were treated without and with the combination of 5 μM perifosine and 12.5 ng/ml TRAIL (PRFS/TRAIL). After 24 h, the cells were
harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect DR5, DR4 and caspase cleavage (A and C)
and for detection of apoptosis with annexin V-flow cytometry (B and D). Columns in B and C are means ± SD of duplicated determinations.
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Page 6 of 13DR5 expression, we transfected JNK-specific siRNA to
inhibit JNK activation through silencing JNK expression
and then examined its impact on DR4 and DR5 expres-
sion. As presented in Figure 5C, transfection of JNK
siRNA reduced basal levels of JNK and p-c-Jun and
abrogated perifosine-induced p-c-Jun increase, indicating
the successful knockdown of JNK and inhibition of JNK
activity. As expected, perifosine induced DR5 expression
in control siRNA-transfected cells, but not in JNK
siRNA-transfected cells. We noted that knockdown of
JNK also reduced basal levels of DR5. Unexpectedly, we
found that knockdown of JNK did not inhibit perifo-
sine’s ability to increase DR4 expression (Figure 5C).
Collectively, we conclude that perifosine induces DR5
expression through a JNK-dependent mechanism.
The Thiol Antioxidants N-acetylcysteine (NAC) and GSH
Inhibit Perifosine-induced JNK Activation and
Upregulation of DR4 and DR5
It was suggested that ROS production is involved in
mediating perifosine-induced DR5 expression [33]. Thus,
we further determined whether this is also the mechanism
underlying perifosine-induced DR4 and DR5 upregulation
in our cell systems. In the presence of a high concentra-
tion of NAC (e.g., 5 mM), perifosine-induced increases in
p-c-Jun, DR4 and DR5 were attenuated (Figure 6A), as
was perifosine/TRAIL-induced apoptosis, as evidenced by
reduced levels of cleaved caspase-8, caspase-3 and PARP
in the cells co-treated with NAC (Figure 6D). In addition,
we further examined the effects of other antioxidants
besides NAC on perifosine-induced JNK activation and
expression of DR4 and DR5, since we assumed that these
antioxidants should also be able to inhibit perifosine-
induced JNK activation and expression of DR4 and DR5 if
ROS indeed plays a role in this process. As presented in
Figures 6B and 6C, we found that GSH, but not vitamin C
or tiron, blocked perifosine-induced increases in p-c-Jun,
DR4 and DR5 to the same extent as NAC. Thus, it appears
that only thiol antioxidants such as NAC and GSH block
perifosine-induced JNK activation and upregulation of
DR4 and DR5.
Perifosine Reduces Total Intracellular Levels of GSH
Without Increasing ROS Generation
We then determined whether perifosine indeed stimu-
lates ROS generation in our cells. Unexpectedly, we
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Figure 4 Perifosine increases cell surface levels of DR5 (A), but not DR4 (B), in M4e cells. M4e cells were treated with PBS or 10 μM
perifosine for 12 h and then harvested for analysis of cell surface DR5 and DR4 by immunofluorescent staining and subsequent flow cytometry.
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Page 7 of 13failed to detect increased ROS production in perifo-
sine-treated cells, while H2O2,a sap o s i t i v ec o n t r o l ,
substantially increased ROS generation (Figure 7A).
Thus, perifosine does not initiate ROS generation in
our cell system. Because of the unique effects of NAC
and GSH on blockage of perifosine-induced JNK
activation and DR4 and DR5 upregulation, we further
determined whether perifosine decreases intracellular
GSH levels. By analyzing the intracellular GSH content
in M4e cells treated with perifosine, we detected
decreased levels of GSH in both time- and dose-
dependent manners after exposure to perifosine
(Figures 7B and 7C). Diethylmaleate (DEM), a positive
control known to be a GSH-depleting agent [34], also
decreased GSH content. Thus, perifosine reduces
intracellular GSH levels.
DEM Weakly Induces DR4 and DR5 Expression, Which Can
Be Enhanced by NAC
If reduction of GSH levels is sufficient to result in upre-
gulation of DR4 and DR5, we assumed that DEM should
induce DR4 and DR5 expression through a similar
mechanism as perifosine does. Thus, we examined the
effects of DEM in the absence and presence of NAC on
D R 4a n dD R 5e x p r e s s i o n .A sp r e s e n t e di nF i g u r e7 D ,
DEM weakly increased the levels of DR4 and DR5 in
M4e cells. We noted that DR4 induction was transient,
since it increased at 4 h and declined at 8 h and particu-
larly at 12 h. The presence of NAC did not inhibit the
induction of DR4 and DR5; instead it enhanced and sus-
tained the expression of DR4 and DR5 induced by DEM.
These data suggest that DEM induces DR4 and DR5
through a different mechanism from perifosine.
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Figure 5 Perifosine activates JNK signaling (A), which mediates DR5 induction by perifosine (B and C). A, M4e cells were treated with 10
μM perifosine for the times indicated. B, M4e cells were pre-treated with the given concentrations of SP600125 for 30 min and then co-treated
with 10 μM perifosine for 12 h. C, M4e cells were transfected with control (Ctrl) or JNK siRNA for 48 h and then treated with PBS or perifosine
for additional 12 h. After the aforementioned treatments, the cells were subjected to preparation of whole-cell protein lysates and subsequent
detection of the indicated proteins using Western blot analysis.
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In agreement with findings in other cell types, we have
demonstrated that perifosine in combination with TRAIL
exhibits enhanced apoptosis-inducing activity in HNSCC
cells. Moreover, we have shown that the combination of
perifosine and TRAIL exhibits enhanced effects on
decreasing clonogenic survival and on inhibiting the
growth of HNSCC xenograft in an orthotopic mouse
model (Figure 1). Thus the current results warrant further
evaluation of the perifosine and TRAIL combination as a
potential therapeutic regimen against HNSCC. We noted
that the perifosine and TRAIL combination was more
effective in decreasing cell survival in M4e and 22A cells
than in 1483 cells, indicating that cell lines have different
sensitivity to the combination. Thus it is important to fully
understand how perifosine cooperates with TRAIL to aug-
ment apoptosis so that we can predict cell sensitivity to
the combination of perifosine and TRAIL.
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Figure 6 Effects of NAC and other antioxidants on perifosine-induced DR4 and DR5 expression (A-C) and on enhancement of TRAIL-
induced apoptosis by perifosine (D). A, M4e cells were pre-treated with the given concentrations of NAC for 30 min and then co-treated with
10 μM perifosine for 12 h; B, M4e cells were pre-treated with 0.5 mM Vitamin C (Vit C), or 0.5 mM tiron for 30 min and then co-treated with 10
μM perifosine for 10 h; C, M4e cells were pre-treated with the given concentrations of GSH for 30 min and then co-treated with 10 μM
perifosine for 10 h. D, M4e cells were pre-treated with 5 mM NAC for 30 min and co-treated with 5 μM perifosine, 12.5 ng/ml and the
combination of perifosine and TRAIL for an additional 12 h. After the aforementioned treatments, the cells were subjected to preparation of
whole-cell protein lysates and subsequent detection of the indicated proteins using Western blot analysis.
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Page 9 of 13In this study, we found that perifosine increased the
expression of DR4 and DR5 in both M4e and 22A cells,
but not in 1483 cells, suggesting the possible involve-
ment of the upregulation of these proteins in perifosine-
mediated augmentation of TRAIL-induced apoptosis
because both proteins are receptors for TRAIL.
Although both DR4 and DR5 upregulation are early
events in cells exposed to perifosine, gene silencing-
mediated blockade of DR5 induction, but not DR4
induction, attenuated apoptosis induced by the perifo-
sine and TRAIL combination (Figure 3), indicating that
DR5 upregulation is a more critical event than DR4
induction for perifosine to augment TRAIL-induced
apoptosis. This finding raised the interesting question of
why DR4 is not involved in modulation of perifosine/
TRAIL-induced apoptosis since it is also upregulated by
perifosine. By analyzing cell surface DR4 and DR5, we
found that perifosine increased cell surface levels of
DR5, but not DR4 (Figure 4). This may, at least in part,
explain why upregulation of DR5, but not DR4, is criti-
cal for mediating augmentation of TRAIL-induced apop-
tosis by perifosine.
DR4 and DR5 induction by perifosine was reported
previously by our group [15,16] and others [33]. How-
ever, how perifosine upregulates DR4 and DR5 has not
been fully elucidated. In this study, we found that Act D
abolished perifosine’s ability to upregulate DR4 and DR5
expression. Moreover, we detected increased levels of
DR4 and DR5 mRNA in cells exposed to perifosine
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Figure 7 Effects of perifosine on ROS generation (A) and GSH levels (B and C) and effects of DEM on DR4 and DR5 expression in the
absence and presence of NAC (D). A, M4e cells were loaded with DCF-DA and then exposed to the indicated concentrations of perifosine
(PRFS) or H2O2 (positive control). At the indicated times post addition of the agents, ROS generation was monitored as described in “Materials
and Methods”. B and C, M4e cells were treated with the indicated concentrations of perifosine or DEM (B) for 9 h or treated with 10 uM for the
given times or 1 mM DEM for 9 h (C). The cells were then subjected to GSH assay as described in “Materials and Methods”. D, M4e cells were
treated with 1 mM DEM in the absence and presence of 5 mM NAC for the indicated times (NAC was added to the cells 30 min before addition
of perifosine). The cells were then lysed for preparation of whole-cell protein lysates and subsequent detection of the indicated proteins using
Western blot analysis.
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Page 10 of 13increases the expression of DR4 and DR5 at the tran-
scriptional level. It has been previously shown that JNK
activation positively regulates DR5 and DR4 expression
induced by certain drugs [32,35,36]. It has also been
documented that perifosine activates JNK signaling
[5-7,37]. A recent study by Tazzari et al. [33] suggests
that perifosine induces a JNK-dependent DR5 expres-
sion in leukemia cells. In our study, we found that peri-
fosine increased the levels of p-JNK and p-c-Jun,
indicating that perifosine also activates JNK signaling.
We noted that JNK signaling activation paralleled the
upregulation of DR4 and DR5. In the presence of the
JNK inhibitor SP600125, perifosine-induced upregula-
tion of both DR4 and DR5 was inhibited (Figure 5).
Interestingly, inhibition of JNK with knockdown of JNK
expression abolished perifosine-induced upregulation of
DR5, but not DR4 (Figure 5C). Thus, it is clear that
perifosine induces JNK-dependent DR5 expression.
Meanwhile, these data also suggest that JNK activation
is not sufficient for perifosine to induce DR4 expression.
Considering the specificity of small molecule inhibitors,
it is important to validate results generated using a
small molecule inhibitor with a specific molecular
approach (e.g., siRNA).
A previous study of leukemia cells has shown that
perifosine induces ROS generation, which contributes to
perifosine-induced DR5 expression. This study primarily
used NAC as the only antioxidant to demonstrate the
involvement of ROS in perifosine-induced DR5 expres-
s i o n[ 3 3 ] .I na g r e e m e n t ,w ef o u n dt h a tN A Ca th i g h
concentrations (e.g., 5 mM) attenuated perifosine’s abil-
ity to increase DR4 and DR5 expression and to augment
TRAIL-induced apoptosis (Figures 6A and 6B). How-
ever, we failed to detect increased ROS generation in
cells exposed to perifosine (Figure 6C). After utilization
of additional antioxidents,w eo b s e r v e dt h a ta n o t h e r
thiol antioxidant, GSH, could also prevent DR4 and
DR5 induction by perifosine, but other two non-thiol
antioxidants, vitamin C and tiron, could not (Figure
6D). These data thus argue against the involvement of
ROS in mediating induction of DR4 and DR5 by perifo-
sine, at least in our cell system. We noted that both
NAC and GSH blocked perifosine-induced JNK activa-
tion and DR4 and DR5 upregulation, whereas vitamin C
and tiron, which did not inhibit perifosine-induced DR4
and DR5 expression, did not affect perifosine-induced p-
c-Jun increase (Figure 6). Therefore, it appears that JNK
activation, but not ROS generation, plays an essential
role in mediating DR5 upregulation by perifosine.
NAC is an aminothiol and synthetic precursor of
intracellular cysteine and GSH and is thus considered
an important antioxidant; however, NAC also possesses
a reducing property through its thiol-disulfide exchange
activity [38]. There are precedents that NAC protects
drug-induced apoptosis through its thiol-disulfide
exchange activity independent of its antioxidant activity
[26,38,39]. In our study, we found that perifosine
decreased the levels of intracellular GSH, as did DEM.
Similarly, a recent study by Simons et al [40] reported
that perifosine increases oxidized levels of GSH and glu-
tathione disulfide (GSSG), and that its combination with
a glutathione-inhibiting agent enhances perifosine’s cell
killing effects in HNSCC cells. It is known that DEM
forms a covalent adduct with GSH via a reaction cata-
lyzed by glutathione-S-transferase, leading to depletion
of intracellular GSH [34]. In our study, DEM weakly
increased DR4 and DR5 expression; which was further
enhanced rather than inhibited by NAC (Figure 7D),
suggesting that perifosine and DEM have different
mechanisms of regulating DR4 and DR5. These findings
also suggest that simple reduction of intracellular GSH
is not sufficient to induce substantial upregulation of
DR4 and DR5. It is possible that perifosine may act
directly on the sulfhydryl (-SH) group of cellular com-
ponents or proteins as other agents do [38], activating
the JNK signaling pathway as well as other mechanisms
and subsequent upregulation of DR5 and DR4. It is also
possible that perifosine activates JNK signaling through
an unknown mechanism, which can be enhanced by
reduction of GSH. Thiol antioxidants may directly inter-
act with perifosine or prevent the reduction of GSH,
leading to abolishing or attenuating perifosine’s ability
to activate JNK and induce DR5 expression. It is known
that glutathione S-transferases (GSTs) inhibit JNK activ-
ity by directly interacting with JNK [41-44]. Moreover,
GSH has been shown to inhibit JNK activity, likely
through affecting the GST-JNK interaction [44]. It is
possible that perifosine directly interacts with sulfhydryl
group of GSTs, releasing GST from its interaction with
JNK and eventually activating JNK. Reduction of cellular
GSH will further enhance this process. Nonetheless,
future studies are needed to demonstrate the potential
role of GSTs in perifosine-induced JNK activation.
It has been suggested that Akt negatively regulates the
JNK signaling pathway [45]. Given that perifosine has
potent Akt-inhibitory activity, it is also possible that
perifosine activates JNK signaling through the release of
Akt-mediated JNK inhibition by inhibiting AKT. We
tested the effect of another Akt inhibitor called API-1
[46] on JNK activation in the same cell system and
found that API-1 also increased p-c-Jun levels (data not
shown). Thus, further study in this direction is also
warranted.
Conclusions
The current study has demonstrated that perifosine
induces a JNK-dependent DR5 upregulation indepen-
dent of ROS generation. Although perifosine induces
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Page 11 of 13expression of both DR4 and DR5, DR5, but not DR4,
induction is critical for cooperative augmentation of
apoptosis by perifosine and TRAIL.
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